ALK-Abelló A/S (ALK-B.CO)
DKK 161.5
(5.56%)
DKK 161.5
(5.56%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 2.20 DKK | 44.74% |
| 2022 | 1.52 DKK | 52.0% |
| 2021 | 1.00 DKK | 809.09% |
| 2020 | 0.11 DKK | 147.83% |
| 2019 | -0.23 DKK | 70.51% |
| 2018 | -0.78 DKK | 2.5% |
| 2017 | -0.80 DKK | -157.97% |
| 2016 | 1.38 DKK | -22.03% |
| 2015 | 1.77 DKK | 88.3% |
| 2014 | 0.94 DKK | 193.75% |
| 2013 | 0.32 DKK | 14.29% |
| 2012 | 0.28 DKK | -72.28% |
| 2011 | 1.01 DKK | 55.38% |
| 2010 | 0.65 DKK | 10.17% |
| 2009 | 0.59 DKK | 22.92% |
| 2008 | 0.48 DKK | -31.43% |
| 2007 | 0.70 DKK | 483.33% |
| 2006 | 0.12 DKK | -99.44% |
| 2005 | 21.40 DKK | 0.0% |
| 2004 | - DKK | 0.0% |
| 2003 | - DKK | 0.0% |
| 2002 | - DKK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 1.10 DKK | 74.6% |
| 2024 Q2 | 0.91 DKK | -17.27% |
| 2023 Q2 | 0.30 DKK | -59.46% |
| 2023 Q1 | 0.74 DKK | 111.43% |
| 2023 Q3 | 0.53 DKK | 76.67% |
| 2023 FY | - DKK | 44.74% |
| 2023 Q4 | 0.63 DKK | 18.87% |
| 2022 FY | - DKK | 52.0% |
| 2022 Q2 | 0.19 DKK | -74.32% |
| 2022 Q3 | 0.24 DKK | 26.32% |
| 2022 Q4 | 0.35 DKK | 45.83% |
| 2022 Q1 | 0.74 DKK | 111.43% |
| 2021 Q3 | 0.17 DKK | 270.0% |
| 2021 Q4 | 0.35 DKK | 105.88% |
| 2021 Q1 | 0.58 DKK | 514.29% |
| 2021 FY | - DKK | 809.09% |
| 2021 Q2 | -0.10 DKK | -117.24% |
| 2020 Q4 | -0.14 DKK | -55.56% |
| 2020 Q1 | 0.40 DKK | 407.69% |
| 2020 Q2 | -0.04 DKK | -111.25% |
| 2020 Q3 | -0.09 DKK | -100.0% |
| 2020 FY | - DKK | 147.83% |
| 2019 Q4 | -0.13 DKK | -102.18% |
| 2019 FY | - DKK | 70.51% |
| 2019 Q1 | 0.21 DKK | 130.88% |
| 2019 Q2 | -0.44 DKK | -309.52% |
| 2019 Q3 | -0.06 DKK | 85.39% |
| 2018 Q2 | -0.08 DKK | -172.73% |
| 2018 Q4 | -0.68 DKK | -466.67% |
| 2018 Q1 | 0.11 DKK | 113.58% |
| 2018 FY | - DKK | 2.5% |
| 2018 Q3 | -0.12 DKK | -50.0% |
| 2017 Q3 | -0.12 DKK | -2252.94% |
| 2017 FY | - DKK | -157.97% |
| 2017 Q4 | -0.81 DKK | -575.0% |
| 2017 Q2 | -0.01 DKK | -150.0% |
| 2017 Q1 | 0.01 DKK | -94.33% |
| 2016 Q4 | 0.18 DKK | -10.0% |
| 2016 FY | - DKK | -22.03% |
| 2016 Q1 | 0.65 DKK | -9.72% |
| 2016 Q2 | 0.35 DKK | -46.15% |
| 2016 Q3 | 0.20 DKK | -42.86% |
| 2015 FY | - DKK | 88.3% |
| 2015 Q3 | 0.30 DKK | 0.0% |
| 2015 Q1 | 0.46 DKK | 455.56% |
| 2015 Q4 | 0.72 DKK | 140.0% |
| 2015 Q2 | 0.30 DKK | -34.78% |
| 2014 Q3 | 0.13 DKK | -18.75% |
| 2014 Q4 | 0.08 DKK | -36.31% |
| 2014 FY | - DKK | 193.75% |
| 2014 Q1 | 0.56 DKK | 166.67% |
| 2014 Q2 | 0.16 DKK | -71.43% |
| 2013 Q3 | 0.05 DKK | 129.06% |
| 2013 Q4 | 0.21 DKK | 351.61% |
| 2013 FY | - DKK | 14.29% |
| 2013 Q1 | 0.22 DKK | 384.24% |
| 2013 Q2 | -0.16 DKK | -172.73% |
| 2012 FY | - DKK | -72.28% |
| 2012 Q4 | -0.08 DKK | -126.69% |
| 2012 Q2 | -0.14 DKK | -170.0% |
| 2012 Q1 | 0.20 DKK | 118.69% |
| 2012 Q3 | 0.29 DKK | 307.14% |
| 2011 FY | - DKK | 55.38% |
| 2011 Q3 | 0.06 DKK | -15.27% |
| 2011 Q1 | 0.64 DKK | 178.26% |
| 2011 Q4 | -1.07 DKK | -2027.93% |
| 2011 Q2 | 0.07 DKK | -89.77% |
| 2010 Q3 | 0.21 DKK | 220.61% |
| 2010 Q1 | 0.38 DKK | 153.33% |
| 2010 Q2 | 0.07 DKK | -82.76% |
| 2010 FY | - DKK | 10.17% |
| 2010 Q4 | 0.23 DKK | 9.52% |
| 2009 Q4 | 0.15 DKK | 7.14% |
| 2009 Q1 | 0.28 DKK | 0.0% |
| 2009 Q3 | 0.14 DKK | 2900.0% |
| 2009 Q2 | -0.01 DKK | -101.79% |
| 2009 FY | - DKK | 22.92% |
| 2008 FY | - DKK | -31.43% |
| 2007 FY | - DKK | 483.33% |
| 2006 FY | - DKK | -99.44% |
| 2005 FY | - DKK | 0.0% |
| 2004 FY | - DKK | 0.0% |
| 2003 FY | - DKK | 0.0% |
| 2002 FY | - DKK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Bavarian Nordic A/S | 19.23 DKK | 88.56% |
| Genmab A/S | 66.64 DKK | 96.699% |
| Gubra A/S | -2.93 DKK | 175.085% |
| Novo Nordisk A/S | 18.67 DKK | 88.216% |
| Orphazyme A/S | -0.74 DKK | 397.297% |
| Pharma Equity Group A/S | -0.02 DKK | 9749.123% |
| Zealand Pharma A/S | -12.44 DKK | 117.685% |